TYME News and Press, Tyme Technologies Inc. From 11/08/21

– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites in early 202...

AVDL, AXSM, BKI, COTY, CTRE, DS,EDIT, EHTH, IMOS, KOS, LINC, LTBR, MTNB, NERV, OCN, PSEC, RDUS, RETA, TGLS, THS, TSEM, TTD, TYME, USFD, VAC, VTRS, WOW For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the...

Company to report its second quarter fiscal 2022 financial results TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announce...

The following slide deck was published by Tyme Technologies, Inc. in conjunction with this event. For further details see: Tyme Technologies (TYME) Investor Presentation

-- Novel oral approach aimed at disrupting cancer metabolism in metastatic HR+/HER2- breast cancer – -- HR+/HER2- represents 73% of diagnoses and is the largest subtype of breast cancer 1 – -- Breast cancer patients from prior first-in-human studies showed broa...

TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financi...

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have address...

Tyme Technologies, Inc. (TYME) Q1 Fiscal Year 2022 Results Conference Call August 10, 2021, 8:30 AM ET Company Participants Richie Cunningham – Chief Executive Officer Frank Porfido – Chief Financial Officer Lisa Wilson – Chief Information Officer Conference Call Particip...

– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsale...